biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (777)	5/24/2005 3:30:35 PM
From: Jibacoa	Read Replies (2) of 3661

Re: EYET The FDA approved Macugen in December in spite of the fact that some patients that received the drug had a significant decrease in vision loss. DNA's Lucentis reportedly has shown improvement of vision in some patients. Several "analysts" have cut their "ratings" on EYET as they feel that in spite of the help on marketing from PFE. Macugen will not be able to compete well with Lucentis. Another stock which was down 15% earlier today (only about 13% at present <g>) is QLTI which also has a product (Visudyne) for treatment of patients with the wet form of AMD. bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next